Insmed 2026 Conference Summary Company Overview - **Company**: Insmed (NasdaqGS: INSM) - **Focus**: Development of treatments for serious, life-threatening conditions, particularly in respiratory diseases - **Commercial Products**: - **ARIKAYCE**: Approved for nontuberculous mycobacteria in refractory settings, with potential label expansion expected in March-April 2026 - **BRINSUPRI**: Launched in August 2025 for bronchiectasis, showing strong market demand [2][3][21] Key Points on ARIKAYCE - **ENCORE Study**: A pivotal study designed to assess the efficacy of ARIKAYCE, focusing on patient-reported outcomes (PRO) and culture conversion rates - **ARISE Study**: A smaller, earlier study that indicated a 4.5-point change in respiratory symptom scores and an 80% culture conversion rate in the treatment arm [5][6][7][9] - **ENCORE Design**: A 12-month study with 425 patients, aiming for a 4-point change in PRO, with a 90% power to detect this change [9][10] - **Patient Population**: Approximately 12,000-17,000 diagnosed patients in the U.S. and 15,000-18,000 in Japan, with a total of about 100,000 in the U.S. and 125,000 in Japan for nontuberculous mycobacteria [11][12] Potential Outcomes from ENCORE - **Success Scenario**: Filing for market approval by the end of 2026, with potential market availability in 2027 - **Mixed Results**: Discussions with the FDA regarding the product's continued availability, given its established patient success [15][19][20] Key Points on BRINSUPRI - **Market Potential**: First and only approved treatment for bronchiectasis, with an estimated 500,000 diagnosed patients in the U.S. - Initial focus on patients with two or more exacerbations, estimated at 250,000 patients [26][27][30] - **Launch Strategy**: A secondary focus on underdiagnosed patients with COPD or asthma, potentially expanding the patient base significantly [30][31] - **Revenue Goals**: Aiming for at least $1 billion in revenue for the year, with peak sales potential estimated at $5 billion [39][40] Other Development Programs - **TPIP**: A new prostacyclin therapy showing promising results in phase 2 studies, with plans for four global phase 3 programs [42][46][47] - **INS1033**: A next-generation DPP1 therapy targeting rheumatoid arthritis (RA) and inflammatory bowel disease (IBD), expected to enter IND by the end of the year [56][57] - **INS1148**: A monoclonal antibody for ILD and asthma, in-licensed with a promising safety profile and efficacy in previous studies [58][59] Conclusion - Insmed is positioned for significant growth with its current product offerings and pipeline, focusing on expanding treatment options for serious respiratory conditions and leveraging its established market presence to capture additional patient populations. The upcoming data readouts and ongoing studies will be critical in shaping the company's future trajectory and market strategy.

Summary of Insmed Conference Call Company Overview - **Company**: Insmed (NasdaqGS:INSM) - **Focus**: Development of treatments for serious, life-threatening conditions, particularly in respiratory diseases - **Commercial Products**: - **ARIKAYCE**: Approved for nontuberculous mycobacteria (NTM) in refractory settings, with a potential label expansion readout expected in March-April 2026 - **BRINSUPRI**: Launched in August 2025 for bronchiectasis, showing strong demand and initial success [2][3][20] Key Points on ARIKAYCE - **ENCORE Study**: A 12-month study designed to assess the primary endpoint of patient-reported outcomes (PRO) and culture conversion rates - **ARISE Study**: A smaller, shorter study that provided preliminary data, showing a 4.5-point change in respiratory symptom scores and an 80% culture conversion rate in the drug arm at the 6-month endpoint [5][6][8][9] - **Patient Population**: Approximately 12,000-17,000 diagnosed patients in the U.S. and 15,000-18,000 in Japan under the current label, with total NTM cases estimated at 100,000 in the U.S. and 125,000 in Japan [11] - **Potential Outcomes**: - Clear win scenario: Filing for market approval by the end of 2026 - Mixed results: Discussion with FDA regarding the product's continued availability due to its established patient impact [14][18][19] Key Points on BRINSUPRI - **Market Potential**: First and only treatment for bronchiectasis, with an estimated 500,000 diagnosed patients in the U.S. - **Initial Focus**: Targeting patients with two or more exacerbations in the past 12 months, estimated at 250,000 patients, with potential for an additional 250,000 patients who may be under-diagnosed [25][26][28] - **Launch Strategy**: A secondary focus on under-diagnosed patients with COPD or asthma, with a potential overlap of 30%-50% of moderate to severe COPD patients also having bronchiectasis [29][30] - **Revenue Goals**: Aiming for at least $1 billion in revenue for the year, with peak sales potential estimated at $5 billion [39] Other Important Developments - **TPIP**: A new prostacyclin therapy showing promising results in phase 2 studies, with a potential peak sales estimate of $2 billion. Four global phase 3 programs are planned to commence [44][46][47] - **INS1033**: A next-generation DPP1 therapy targeting rheumatoid arthritis (RA) and inflammatory bowel disease (IBD), expected to progress through IND by the end of the year [53][54] - **INS1148**: A monoclonal antibody recently acquired for ILD and asthma, showing promise in previous studies and expected to enter clinical trials soon [55][56] Conclusion Insmed is positioned for significant growth with its innovative therapies targeting serious respiratory conditions. The upcoming data readouts and market strategies for ARIKAYCE and BRINSUPRI are critical for the company's future success, alongside the development of new therapies like TPIP and INS1033.

Core Insights - Insmed reported total revenues of $606.4 million for the full year 2025, with significant contributions from its products BRINSUPRI and ARIKAYCE [1][2] - The company anticipates full-year 2026 revenues for BRINSUPRI to be at least $1 billion and for ARIKAYCE to be between $450 million and $470 million [1][2] - Insmed's net loss for the fourth quarter of 2025 was $328.5 million, compared to a net loss of $235.5 million in the same quarter of 2024 [2][3] Financial Performance - Total revenues for the fourth quarter of 2025 were $263.8 million, a 153% increase compared to $104.4 million in the fourth quarter of 2024 [2] - ARIKAYCE revenues for the fourth quarter of 2025 were $119.2 million, reflecting a 14% growth year-over-year, while full-year revenues reached $433.8 million, a 19% increase from 2024 [2] - BRINSUPRI generated $144.6 million in the fourth quarter and $172.7 million for the full year 2025, marking its successful U.S. commercial launch [1][2] Research and Development Updates - Insmed is advancing its clinical programs, including the Phase 3 ENCORE trial for ARIKAYCE and additional Phase 3 studies for TPIP in patients with pulmonary conditions [1][2] - The company plans to submit a supplementary new drug application for ARIKAYCE in the second half of 2026, pending positive topline data from the ENCORE trial [1][2] - Insmed is also developing INS1148 and INS1201, targeting various respiratory and genetic diseases, with IND filings expected in 2026 [1][2] Cash Position and Future Guidance - As of December 31, 2025, Insmed had approximately $1.4 billion in cash, cash equivalents, and marketable securities, positioning the company for continued investment in its pipeline [1][2] - The company expects to maintain a focus on commercialization and expansion of its product offerings, particularly BRINSUPRI and ARIKAYCE, throughout 2026 [1][2] - Insmed anticipates that pre-clinical research programs will comprise less than 20% of overall expenditures, indicating a strategic focus on advancing clinical development [2]

February 2026 Investor Presentation We're in. For patients. 1 Forward Looking Statements The forward-looking statements in this presentation are based upon the Company's current expectations and beliefs, and involve known and unknown risks, uncertainties and other factors, which may cause the Company's actual results, performance and achievements and the timing of certain events to differ materially from the results, performance, achievements or timings discussed, projected, anticipated or indicated in any ...

Summary of Insmed's Conference Call Company Overview - **Company**: Insmed - **Industry**: Biotechnology, specifically focusing on respiratory, immunology, inflammation, and rare diseases Core Points and Arguments Product Highlights - **Brensocatib**: Recently approved for non-cystic fibrosis bronchiectasis, showing significant patient impact with a reduction in CAT score from 32 to 6 and a 15% increase in FEV1 after four weeks of treatment [2][3] - **Arikayce**: Approved for refractory MAC lung disease, targeting $450-$470 million in revenue for the year, with strong international performance [10][11] - **TPIP**: A new inhalation powder for pulmonary hypertension and interstitial lung disease, with ongoing phase three trials [12][13] - **INS1148**: A newly acquired monoclonal antibody targeting respiratory and inflammatory bowel diseases, expected to show efficacy similar to previous studies in atopic dermatitis [15][16] Market Performance - Insmed's market cap has increased by an average of $2 billion per month over the last 18 months [6] - Brensocatib added 9,000 patients in its first full quarter, totaling over 11,500 since launch, with impressive revenue of $144.6 million in Q4 [8][9] Future Growth and Development - Insmed aims to expand its therapeutic areas and is open to business development opportunities beyond its current focus [29] - The company is targeting a total addressable market of 250,000 patients for bronchiectasis, with potential upside from comorbid conditions like COPD and asthma [57][58] Clinical Trials and Pipeline - Upcoming trials include the Encore trial for Arikayce and multiple phase three studies for TPIP [10][12] - The CEDAR trial for Brensocatib in hidradenitis suppurativa is set to read out in Q2 2026, with a focus on achieving a 20% reduction in AN count [16] Challenges and Considerations - The company acknowledges potential challenges such as out-of-pocket reset dynamics and insurance authorization processes that could impact drug uptake [9][55] - The recent failure of a DPP-1 trial for CRS has led to a reevaluation of expectations for Brensocatib's application in other disease states [61][62] Additional Important Content - Insmed has a strong cash position of $1.7 billion as of September, allowing for continued investment in clinical and commercial opportunities [24] - The company has been recognized as a top biopharma employer for five consecutive years, reflecting a strong internal culture [25] - The launch of Brensocatib is seen as a potential catalyst for a virtuous cycle of increased prescriptions as patient success stories circulate [51][53] Conclusion - Insmed is positioned for significant growth with its innovative therapies and strong market performance, while also navigating challenges in the healthcare landscape. The focus on patient impact and expanding therapeutic areas will be crucial for future success.

Financial Performance & Guidance - BRINSUPRI achieved preliminary unaudited U S net revenues of approximately $144 6 million in Q4 2025 and $172 7 million for the full year 2025[23] - ARIKAYCE generated worldwide revenue of approximately $433 8 million in FY 2025, representing a 19 3% increase year-over-year[27] - The company anticipates ARIKAYCE revenue to be between $450 million and $470 million for the full year 2026[28] Clinical Development Programs - The company expects topline data readout from the Phase 3 ENCORE trial for ARIKAYCE in March/April 2026, potentially leading to label expansion[30, 31] - Phase 3 trials for TPIP in PAH, PPF, and IPF are expected to initiate in early and the second half of 2026 respectively[13, 38] - Topline data readout from the Phase 2 CEDAR trial for brensocatib in Hidradenitis Suppurativa is expected in Q2 2026[46, 50] Pipeline Expansion - The company plans to file Investigational New Drug (IND) applications for RA and IBD in the second half of 2026[13, 50] - IND filing for Stargardt is anticipated in 2026[13, 59] - Phase 2 programs in ILD and moderate to severe asthma are planned for INS1148[13, 40] Commercial Expansion - BRINSUPRI is expected to launch in the EU and UK, pending regulatory approval[13, 44] - BRINSUPRI is also anticipated to launch in Japan, pending regulatory approval[13, 44] Cash Position - The company reported a cash position of $1 7 billion as of September 30, 2025[62]

Core Insights - Insmed's shares have increased by 78% over the past six months, driven by strong momentum from its late-stage pipeline and robust sales from marketed drugs, enhancing investor confidence [1] Group 1: Product Approvals and Market Potential - The FDA approved brensocatib, branded as 'Brinsupri', in August 2025, making it the first approved therapy for non-cystic fibrosis bronchiectasis (NCFB) [2] - Brinsupri's approval positions Insmed to access a multi-billion-dollar market and marks the company's second marketed product, generating $28.1 million in revenues in Q3 2025 due to strong patient uptake [3] - Insmed's shares surged following the approval of Brinsupri, reflecting its strong revenue potential [7] Group 2: Financial Performance - Over the past year, Insmed's shares have surged by 149.2%, significantly outperforming the industry growth of 17.5% [4] - Arikayce, Insmed's established product, generated $314.5 million in sales in the first nine months of 2025, reflecting a 21% year-over-year increase, which alleviates near-term cash flow concerns [5] - Following the third-quarter release, Insmed raised its full-year guidance for Arikayce revenues to a range of $420 million to $430 million, up from $405 million to $425 million [8] Group 3: Pipeline Developments - Insmed faced a setback with the phase IIb BiRCh study of brensocatib in chronic rhinosinusitis without nasal polyps, which failed to meet key efficacy goals, leading to the discontinuation of this indication [9] - Despite this, Insmed is strengthening its pipeline with the addition of INS1148 for interstitial lung disease and asthma, and is evaluating brensocatib in the phase II CEDAR study for hidradenitis suppurativa, with data expected in the first half of 2026 [10] - Insmed is also progressing treprostinil palmitil inhalation powder into late-stage studies for pulmonary hypertension indications [12]

Core Viewpoint - Insmed Incorporated's stock experienced a significant decline following the release of disappointing results from the Phase 2b BiRCh study of brensocatib for chronic rhinosinusitis without nasal polyps (CRSsNP) [2][8]. Study Results - The Phase 2b BiRCh study did not meet its primary or secondary efficacy endpoints for both the 10 mg and 40 mg treatment arms, indicating a lack of treatment benefit [2][4]. - The study reported the following least squares (LS) mean changes in the primary endpoint: placebo at -2.44, brensocatib 10 mg at -2.21, and brensocatib 40 mg at -2.33, showing minimal improvement [5]. Development Program Update - Insmed has decided to discontinue the development program for brensocatib in CRSsNP effective immediately and plans to present the study data at a future congress [3][4]. New Acquisition - Insmed acquired INS1148, an investigational monoclonal antibody aimed at treating respiratory and immunological diseases, with plans to advance its Phase 2 development in interstitial lung disease and moderate-to-severe asthma [6]. Analyst Insights - Analysts noted the inherent clinical risks associated with the BiRCh study due to the lack of prior data on DPP1 inhibition in CRSsNP [7]. - Despite the setback with CRSsNP, analysts believe that Brinsupri will have a strong market launch for bronchiectasis, and other lead programs like Arikayce and TPIP present meaningful expansion opportunities [7]. - RBC Capital has lowered its price target for Insmed from $215 to $195 while maintaining an Outperform rating, and Guggenheim has also lowered its price target from $230 to $221 while keeping a Buy rating [8]. Stock Performance - Following the news, Insmed's stock fell by 15.28%, trading at $168.14 at the time of publication [8].

Core Insights - Insmed's recent clinical trial for brensocatib faced setbacks, leading to a significant drop in share price, which fell nearly 17% to around $165 after the announcement of the failed trial [3][7] - Despite the setback, analysts believe it should not drastically alter the overall positive narrative surrounding the company, with expectations for continued sales growth from Brinsupri and other products [4][5] Company Performance - Insmed had previously reported promising results for brensocatib in bronchiectasis, receiving approval in August 2025 and exceeding analyst sales estimates for the third quarter [3] - The company’s stock had seen a substantial increase, rising from approximately $25 a year and a half ago to above $200 recently [7] Clinical Trials and Research - The Phase 2b study aimed to expand the use of brensocatib to treat chronic rhinosinusitis without nasal polyps but yielded no benefits from the tested doses [5][7] - Insmed announced a new acquisition of a monoclonal antibody, INS1148, which is set to enter Phase 2 research targeting respiratory and immunological diseases, with initial tests planned for interstitial lung disease and moderate-to-severe asthma [6] Analyst Perspectives - RBC Capital Markets analyst Leonid Timashev expressed that while the recent trial results are disappointing, they do not fundamentally change the outlook for Insmed, projecting sales of nearly $700 million for Brinsupri next year [4] - The company is also exploring the potential for brensocatib to be used in treating hidradenitis suppurativa, indicating ongoing research and development efforts [4]

Core Insights - Insmed Incorporated announced that the Phase 2b BiRCh study of brensocatib in chronic rhinosinusitis without nasal polyps (CRSsNP) did not meet its primary or secondary efficacy endpoints, leading to the discontinuation of the development program for this indication [1][2][4] - The company has acquired INS1148, a Phase 2 ready monoclonal antibody aimed at treating respiratory and immunological diseases, which is expected to advance into clinical development [3][4] Study Results - The Phase 2b BiRCh study involved 288 patients randomized to receive either brensocatib 10 mg, 40 mg, or placebo for 24 weeks, with the primary endpoint being the change in the 28-day average of daily Sinus Total Symptom Score (sTSS) at Week 24 [4][5] - Topline results showed that the placebo group had a least squares mean change of -2.44, while the brensocatib 10 mg and 40 mg groups had changes of -2.21 and -2.33, respectively, indicating no significant improvement [2][4] - Treatment-emergent adverse events (TEAEs) were reported as follows: 63.6% for 10 mg, 69.9% for 40 mg, and 65.3% for placebo, with serious TEAEs being 2.0%, 3.2%, and 2.1% respectively [2] Acquisition Details - INS1148 is an investigational monoclonal antibody with a novel mechanism targeting a specific isoform of Stem Cell Factor SCF248, which may address significant unmet needs in respiratory and inflammatory diseases [3][4] - The company plans to initiate Phase 2 development programs for INS1148 in interstitial lung disease and moderate-to-severe asthma [3][4] Company Overview - Insmed is a biopharmaceutical company focused on delivering innovative therapies for serious diseases, with a diverse portfolio that includes both approved and investigational medicines [6][7] - The company has been recognized as a top employer in the biopharmaceutical industry, emphasizing its commitment to patient care and innovative drug development [7]